Colorectal

Chemoradiotherapy Plus Consolidation Chemo Feasible Strategy for Locally Advanced Rectal Cancer

07/04/2019

Results from a phase 2 “pick the winner” trial presented at the ESMO 21st World Congress on Gastrointestinal Cancer suggest upfront chemoradiotherapy followed by consolidation chemotherapy may be a feasible strategy for total neoadjuvant...

Results from a phase 2 “pick the...

07/04/2019

Oncology

Cost of Drugs for Metastatic CRC Per Month of Life Gained Vary Widely in Spain

07/02/2019

A wide variation exists in the cost per month of life gained for drugs administered in different lines of therapy for patients with metastatic CRC in Spain.

A wide variation exists in the...

07/02/2019

Oncology

Videos

Eric Van Cutsem, MD, PhD, Discusses the Novel Therapies and Targets in Metastatic CRC

03/29/2019

At the 2019 Great Debates & Updates in GI Malignancies meeting, Dr Van Cutsem talked about the novel therapies and targets in metastatic CRC.

At the 2019 Great Debates &...

03/29/2019

Oncology

TNT vs Conventional Radiotherapy for Locally Advanced Rectal Cancer

03/29/2019

Christopher H. Crane, MD, and Noam VanderWalde, MD, MS, went head-to-head on the use of TNT vs preoperative conventional radiotherapy in patients with locally advanced rectal cancer.

Christopher H. Crane, MD, and...

03/29/2019

Oncology

Experts Debate Evidence For and Against HIPEC Use in CRC Peritoneal Disease

03/29/2019

Michael A. Choti, MD, and Andrea Cercek, MD, presented their arguments for and against the use of HIPEC for CRC peritoneal carcinomatosis at the 2019 Great Debates and Updates in GI Malignancies meeting.

Michael A. Choti, MD, and Andrea...

03/29/2019

Oncology

Videos

Atezolizumab Combination is Not Superior to Standard of Care for Chemotherapy-Refractory Metastatic Colorectal Cancer

07/07/2018

Josep Tabanero, MD, discusses the results of the phase 3 IMblaze70 trial comparing atezolizumab plus cobimetinib and atezolizumab monotherapy versus standard-of-care regorafenib in chemotherapy-refractory metastatic colorectal cancer.

Josep Tabanero, MD, discusses...

07/07/2018

Oncology

Atezolizumab Combination Not Superior to Regorafenib for Refractory mCRC

06/22/2018

A phase III study comparing atezolizumab plus cobimetinib and atezolizumab monotherapy vs standard-of-care regorafenib in chemotherapy-refractory metastatic colorectal cancer did not reveal any significant differences in outcomes.

A phase III study comparing...

06/22/2018

Oncology

Real-World Outcomes of Regorafenib for mCRC Reflect Clinical Trials

06/22/2018

Patients with metastatic colorectal cancer treated in the real-world setting experienced comparable survival benefits and safety outcomes compared with clinical trials, despite flexible dosing.

Patients with metastatic...

06/22/2018

Oncology

Should Patient Selection for Colorectal Cancer Metastasectomy Involve Molecular Analysis?

03/23/2018

Cathy Eng, MD, and Michael Choti, MD, offered varying opinions regarding whether molecular characteristics play a role in selecting patients with colorectal cancer for metastasectomy.

Cathy Eng, MD, and Michael...

03/23/2018

Oncology

Is Salvage Regorafenib or Enhanced Immunotherapy Optimal for Refractory Colon Cancer?

03/23/2018

Andrea Cercek, MD, and Neil Segal, MD, PhD, offered different stances on the optimal salvage therapy for refractory colon cancer.

Andrea Cercek, MD, and Neil...

03/23/2018

Oncology